Cost-effectiveness of Glaucoma Screening
Author Information
Author(s): Anja Tuulonen
Primary Institution: University of Oulu and Tampere University Hospital, Finland
Hypothesis
Is systematic population screening for glaucoma cost-effective in developed countries?
Conclusion
There is currently insufficient evidence to determine if systematic population screening for glaucoma is cost-effective in developed countries.
Supporting Evidence
- Glaucoma is the second most common cause of visual disability in the elderly in developed countries.
- More than half of glaucoma patients are undiagnosed.
- Half of the patients treated for glaucoma do not have the disease.
Takeaway
This study looks at whether screening for glaucoma is worth the money in developed countries, and it finds that we don't have enough information to say yes or no.
Methodology
The article reviews existing literature on the cost-effectiveness of glaucoma screening and discusses the need for future research.
Potential Biases
Potential biases exist due to the reliance on limited and possibly non-representative studies.
Limitations
The evidence on the cost-effectiveness of screening is limited and varies by population and definitions of glaucoma.
Participant Demographics
The study discusses glaucoma in the context of developed countries, particularly focusing on elderly populations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website